PPAR-ɣ is known to enhance insulin sensitivity in peripheral tissues [134], and synthetic PPAR-ɣ agonists, such as pioglitazone and rosiglitazone, are approved by the FDA for treatment of T2D [134]. This evidence concerns the gene INS and type 2 diabetes mellitus.